Purpose. There have been hardly any reports on the human immunodeficiency virus type 1 (HIV-1) drug-resistance profile from northern Ghana since antiretroviral therapy (ART) was introduced over a decade ago. This study investigated prevailing HIV-1 subtypes and examined the occurrence of drug resistance in ART-experienced patients in Tamale, the capital of the Northern Region of Ghana.
INTRODUCTION
In Ghana, the human immunodeficiency virus (HIV) prevalence has continued to decline over the past 14 years, from a peak of 3.6 % in 2003, following the implementation of strategies by the National AIDS Control Programme towards achieving universal access to antiretroviral therapy (ART) [1] . The 2016 national HIV prevalence was 1.6 %; with regional prevalence ranging from the highest (2.7 %) in the Volta and Brong Ahafo Regions to the lowest in the northern regions of the country. The Northern Region, where this study was conducted, is the largest of the ten regions in Ghana. It has very low population density, is relatively less resourced and is also the region with the lowest HIV prevalence of 0.7 % [2] [3] [4] . By the end of 2015, since the scale-up began in June 2003, ART services had been expanded to 197 health facilities including 17 private selffinancing facilities in 145 out of the 216 districts in all ten regions; and an estimated 89 113 out of 274 562 (~32 %) of people living with HIV (PLHIV) and needing treatment enrolled at the various facilities for ART treatment, care and support [5] .
In contrast to its relatively low HIV prevalence, it is striking to note that in 2014, for example, the Northern Region recorded 4787 orphaned and vulnerable children, representing 15.5 % of the total nationwide and the highest recorded in all ten regions. Besides, enrolment of PLHIV and their clients or dependants for ART service uptake appears low [6] . Until now data is lacking regarding ART outcome in northern Ghana. Attention and funding for HIV programmes in the Northern Region is often less in comparison to more population-dense regions and urban centres of Ghana, probably because of its low HIV prevalence ranking. Besides, there are certain complex belief systems and practices that constitute barriers in the north, which involve diverse traditional beliefs and socio-cultural practices, economics, medicine, psychology and a knowledge gap that affect stigma and discrimination with respect to HIV/AIDS.
At its special session in 2014, The Joint United Nations Programme on HIV and AIDS (UNAIDS) adopted a post-2015 roadmap -the 90À90À90 targets for ending the AIDS pandemic by 2030. Ghana is a priority country among 35 fasttrack countries identified as accounting for 90 % of people newly infected with HIV globally. Besides, the UNAIDS identified Ghana as a priority country for implementation of the 90À90À90 initiative aimed at diagnosing 90 % of all those infected with HIV globally and reaching 90 % of the population of PLHIV with treatment and ensuring viralogical suppression in 90 % of all patients in treatment by 2020 [7, 8] . However, antiretroviral drug-resistance emergence and drug-resistant HIV transmission affect the efficacy of ART [9, 10] and therefore constitute a formidable hurdle to the attainment of the third À90 target. Thus, to enhance the achievement of the targets for ending AIDS, there is a need for concomitant ART monitoring.
Surveillance to monitor HIV drug resistance in ART programmes remains even more crucial in resource-limited settings where routine HIV drug-resistance testing is lacking and assessment of quality-assured virological response to ART is limited [11, 12] . Pragmatic measures are therefore necessary, especially where resources are limited. Thus, to attain set targets, Ghana adopted a five-year roadmap -The 90À90À90 Ghana Campaign Ending the AIDS Epidemic by 2030 roadmap, that set out national health sector plans to mobilize all stakeholders to locate, test, treat and retain PLHIV in ART care. The roadmap presents ongoing virologic monitoring as central to attainment of the third À90 target; and underscores HIV VL as the standard parameter for monitoring patients on ART in Ghana. As such, previous drug resistance and VL data could serve as an important reference point to decipher trends.
Furthermore, Ghana has a major port/harbour that serves other countries inland of West Africa. There are reports implicating long-distance truck drivers as potential transmitters of infections including HIV, due to their long periods of stay away from home [13] [14] [15] . Tamale, the region of our study is a major stop-over for long-distance truck drivers from countries beyond northern Ghana. There is however no report of HIV molecular epidemiology in this region. This study therefore examined virological efficacy and the drug-resistance profile in adult HIV/AIDS patients in 2010. Concomitantly, the study analysed in detail the prevailing HIV-1 subtypes to further understand the epidemiology of HIV-1 infections in Ghana.
METHODS
Study setting, design and participants HIV-infected patients who accessed antiretroviral treatment services and care at Tamale Teaching Hospital in the Northern Region of Ghana were studied. The study hospital is the regional hospital in Tamale, the capital of the Northern Region of Ghana. It is the third teaching hospital in Ghana after Korle Bu and the Komfo Anokye Teaching Hospitals; and serves as a referral hospital for the three northern regions of Ghana. HIV prevention and intervention programmes including the provision of free ART services to HIV-infected patients are part of the hospital's health care delivery system. At the time of the study, the estimated number of individuals accessing ART in the region was about 1047; and about 400 of these were accessing care at the Tamale regional hospital [16] . Of the 52 regular attendees who consented to participate, only 33 were found eligible for the study. Some of the factors accounting for low ART uptake in the study area have been considered in Discussion.
All ART-receiving patients were assessed using a standardized format. ART was initiated in accordance with the WHO's recommendations for ART scale-up in resourcelimited settings. Patients on first-line ART were eligible for the study. A cross-sectional virological efficacy study of patients on ART was carried out between January 2009 and February 2010. The study involved adults (15 years and over) who had received first-line ART for at least 4 months. First-line treatment regimen comprised zidovudine, or stavudine combined with lamivudine, and either nevirapine or efavirenz. Patients who had been off treatment for 1 month or more were considered to have stopped and so were excluded; and those who were on second-line ART were also excluded in view of the fact that genotypic-resistance data were not acquired prior to the switch. Immune cell count and plasma HIV-1 VL assay To assess immune response, CD4 + T-cell counts were obtained by using a FACSCount flow cytometer (Becton Dickinson, San Jose, CA, USA) at the study site. Plasma HIV-1 viral load (pVL) was measured at Noguchi Memorial Institute for Medical Research (NMIMR) using an in-house real-time reverse transcription followed by PCR (RT-PCR) assay with a lower detection limit of 180 copies ml À1 , according to the method of Barnor et al. [17] . Patients who had been on ART for more than 3 months and had pVL more than 200 copies ml À1 were considered as virological failures.
HIV-1 drug-resistance genotyping HIV-1 drug-resistance genotyping was conducted at the Clinical Research Laboratory of the Department of Infection and Immunology, Nagoya Medical Center in Japan. Genotyping was performed as previously reported with some modifications [18] . Briefly, viral RNA was extracted from 200 µL of plasma samples using QIAamp viral RNA mini kit (Qiagen, Hilden, Germany). RT-PCR was performed using QIAGEN one-step RT-PCR kit; and was followed by nested PCR by the use of AmpliTaq deoxyribonucleic acid (DNA) polymerase (Applied Biosystems, Foster City, USA) protocol to further amplify the protease (PR) and reverse transcriptase (RT) regions. The primers used were the same as previously reported [18] . Generated DNA fragments of 424 bp in the PR region (positions 2168 to 2591 in the reference HXB2 sequence) and 838 bp of the RT region (positions 2510 to 3347) were sequenced using an ABI 3730 auto-sequencing system. Sequences were edited with SeqScape software v2.5 (Applied Biosystems) and HIV-1 drugresistance mutations were interpreted according to the 2017 resistance mutations update by the International Antiviral Society of USA panel [19] .
Phylogenetic and recombination analyses
Altogether, 24 of the available isolates comprising 21 PR-RT and three RT sequences of the pol gene were subtyped. HIV-1 subtyping was initially performed and confirmed separately for the 21 PR-RT fragments (1095 bp spanning positions 2253 to 3347 of the reference HXB2 sequence) and also for the three RT sequence fragments (798 bp spanning positions 2550 to 3347 of the reference HXB2 sequence). However, for the purpose of simplification, the phylogenetic tree presented here was constructed using only the RT gene of all 24 isolates in view of the similarity in the phylogenetic pattern they generate. The phylogenetic tree was constructed by, first, aligning test sequences with references of pure subtypes AÀD, FÀH, J, K, and all circulating recombinant forms (CRFs) 01 to 88, except 66, 75, 77, 79-84, which were accessed from the HIV Sequence Database of Los Alamos National Laboratory [20] Also included in the subtyping analysis were HIV-1 sub-subtypes A3 (DDI579, DDJ360 and DDJ369) and A4 (97 CD_KCC2, 97 CD_KTB13 and 02 CD_KTB035) isolates, which have been reported to be circulating in some African countries [21, 22] . Multiple sequence alignment was then performed by using the MUSCLE program; genetic distances were determined based on the Kimura two-parameter model; and phylogenetic trees were generated by the neighbour-joining method with 1000 bootstrap replicates to estimate the reliability of the branching clusters. All phylogenetic and molecular evolutionary analyses were conducted using MEGA version 7 [23] .
To clarify recombination, similarity plotting and boot-scanning were performed using SimPlot software version 3.5.1 [24] with window and step sizes of 300 and 20 base pairs respectively. The nine group M HIV-1 phylogenetic subtypes AÀD, FÀH, J and K; and CRF02_AG were used as references in the SimPlot analyses.
Statistical analysis
Analysis of statistical significance between categorical and quantitative variables were respectively performed by Fisher's exact test and the MannÀWhitney U-test programs implemented in GraphPad Prism version 6.07 for Windows (GraphPad Software, San Diego CA, USA, www.graphpad. com). All tests were two-sided with the level of significance set at P=0.05.
Sequence repository
Nucleotide sequences described in this study have been registered and deposited in the DNA databank of Japan under the accession numbers LC269861-LC269884.
RESULTS

Participants, immunological and virological indices
A total of 33 HIV-1-infected ART-experienced adults (!15 years old) were studied. The participants comprised 11 males and 22 females; with a median age of 34.5 years (IQR: 30.0-40.3). Table 1 shows details of the demographic and clinical characteristics of the study subjects. The median CD4 + T-cell count was 404 cells µl
À1
. Six patients (18.2 %) had a CD4 + T-cell count <200 cells µl
. Overall, 23 patients (69.7 %) had HIV RNA (<200 copies ml À1 ); a total of 28 had <1000 HIV RNA copies ml À1 ; and the remaining five patients had VL of >1000 copies ml
. Subjects for whom VL results were obtained were included for drug-resistance analyses. A CD4 + T-cell count was not available for two of the 33 patients included in the study.
HIV-1 subtype prevalence in Tamale, northern Ghana Detailed molecular analyses of the HIV-1 pol gene sequences were performed to help elucidate the molecular epidemiology of HIV-1 infections in the northern part of Ghana. Nine samples, which had pVL below 200 copies ml À1 , were unsuccessful in gene amplification despite repeated attempts and by use of alternative, customized primers. There was however no significant difference (MannÀWhitney U-test, P=0.10628) between the VL of success and failure cases. HIV-1 pol gene sequences were therefore available for 24 cases. Phylogenetic analysis, similarity plotting and bootscanning identified 91.7 % (22/24) of the isolates as HIV-1 subtypes and CRFs (Fig. 1) . Overall, 19 out of the 24 isolates (79.2 %) were CRF02_AG, two (8.3 %) were subtype G and one (4.2 %) was sub-subtype A3. Similarity plotting and boot-scanning analyses (Fig. 2) identified two (8.3 %) of the isolates as having unknown mosaic pattern of CRF02_AG/ A3 (Fig. 2) . For one (Fig. 2a) , the recombination fragments were 2550-3295 (CRF02_AG) and 3296-3347 (A3), with breakpoint at position 3295; and for the other (Fig. 2b) , the recombinant fragments were 2550-2668 (CRF02_AG), 2669-2842 (A3), 2843-3216 (CRF02_AG) and 3217-3447 (A3), with breakpoints at positions 2668, 2842 and 3216 (the positions were numbered according to that of the pol gene of HXB2 reference sequence, GenBank accession no. K03455). The two isolates were considered as unique recombinant forms (URFs). In general however, these findings highlight the predominance of HIV-1 CRF02_AG and dynamic viral genetic recombination in Tamale, Ghana.
HIV-1 drug-resistance mutations among ARTexperienced adults in Tamale All 33 patients studied were treated with the first-line antiretroviral regimen of two NRTIs+NNRTI; most of who received zidovudine (60.6 %) or stavudine (24.2 %) with lamivudine and nevirapine (AZT/3TC/NVP or d4T/3TC/NVP). The median duration of ART at the time of the study was 12 months (IQR, 8-24 months). Gene amplification was not successful for nine samples. Genotypic tests were therefore performed on 24 (72.7 %, 24/33) of the study subjects. A total of 14 (58.3 %, 14/24) of the cases tested had no mutations; whereas each of the remaining 41.7 % (10/24) had !1 mutation conferring drug resistance to NRTIs or NNRTIs ( Table 2 ).
The most common drug-resistance pattern was two-class resistance to NRTI and NNRTI (n=6, 25 %), followed by oneclass resistance to either NRTI or NNRTI (n=2, 8 % in each case). The most prevalent NRTI and NNRTI mutations were M184V and K103N respectively (n=6, 25 % in each case) (Table 2a) . Two patients' viruses harboured multi-NRTI resistance mutations: one had A62V and the other harboured F116Y and Q151M multi-NRTI mutations in addition to K103N, Y181C and M184V multidrug resistance profiles, making this virus resistant to all the NRTIs as well as EFV and NVP (Table 2b ). One patient also had K65R mutation which confers resistance to most NRTIs. Other mutations -E138A in one patient and V90I in four patients À were also detected, which are NNRTI-resistance associated but not responsible for resistance to EFV or NVP prescribed.
Considering the occurrence of drug-resistant mutations and clinical outcome, one of five patients with virological failure had no drug-resistance mutation (data not shown), which might suggest that virological failure could be due to causes other than acquisition of drug resistance. Cases with virological failure had been on ART for a duration varying from 8 months to 3 years. One case had been on ART for 4 years with good virological suppression. The cases with or HIV-1 subtypes of 24 Ghanaian isolates were determined through phylogenetic tree construction, similarity plotting and boot-scanning analyses of HIV-1 RT sequences. The evolutionary history was inferred using the neighbour-joining method; and the evolutionary distances were computed using the Kimura two-parameter method. Bootstrap values were obtained from 1000 replicate analyses and values exceeding 70 % are shown at tree nodes. The tree displays the Ghanaian isolates classified into known subtypes, CRFs and URFs, which are represented by coloured circles (red for CRF02_AG, blue for subtype G, yellow for subtype A3 and green for URF); and subtype reference isolates, which are represented by the subtype and isolate name. The scale represents the number of nucleotide substitutions per site. HIV-1 group O isolate, ANT70, was used as the outgroup. Evolutionary analyses were conducted in MEGA7. RT, reverse transcriptase; CRF, circulating recombinant form; and URF, unique recombinant form.
without resistance mutations did not differ significantly in their demographic characteristics.
DISCUSSION
This study presents the prevalence of circulating HIV-1 subtypes and a profile of drug resistance to HIV-1 antiretroviral treatment in Tamale in the Northern Region of Ghana. The findings unambiguously present HIV-1 circulating recombinant form, CRF02_AG as the predominant subtype (79.2 %, 19/24) in the region. Previous studies, mainly in the mid-tosouthern parts of Ghana, have identified the CRF02_AG as dominating HIV infections in the country [18, [25] [26] [27] [28] . Data is lacking as to whether this dominance also pertains to the northern parts, which share a border with neighbouring Burkina Faso, where CRF06_cpx rather than CRF02_AG is predominant and also other unique forms involving subtypes B, D and K appear to circulate [29, 30] . Thus, in agreement with previous reports, the findings of this study adds to data identifying the CRF02_AG as predominating Ghanaian HIV infections, for nearly two decades following its identification in 1997 [18, 25-28, 31, 32] . It is however important to note that some of the studies over the past ten years have identified various URFs [18, 27] -an indication of active, on-going viral recombination, which may lead to the emergence of a new predominant HIV-1 subtype in the future.
Another important finding of this study is the presence of a unique HIV-1 mosaic form -a recombinant of HIV-1 CRF02_AG and sub-subtype A3, which mostly circulate in West Africa. This together with previous data suggests that the CRF02_AG/A3 URF may be a new CRF spreading in Ghana and probably other West African countries. This underscores the importance of continued monitoring of molecular epidemiology and clinical relevance of HIV subtype variations. Boot-scanning was performed using the neighbour-joining algorithm modelled with the Kimura two-parameter method for 100 replicates. Similarity plotting and boot-scanning were generated in SimPlot version 3.5.1 with parameter settings of simple consensus sequences; and window and step sizes of 300 and 20 nucleotides respectively. For all panels the x-axis indicates the nucleotide positions along the alignment (gaps were removed from the alignment). Reference sequences are colour-coded and listed on the right of each plot. Points of crossover of the two curves indicate recombination breakpoints. The analyses confirm the presence of a unique recombinant profile of CRF02_AG/A3.
With respect to the outcome of ART in the population under study, the proportion of patients with drug-resistance mutations was 41.7 %. Four out of five (80 %) of the patients with virological failure had one or more drug-resistance mutations. This observation may suggest drug resistance as the major risk factor for virological failure, which is in conformity with several of previous study findings [33] [34] [35] [36] . Adherence data, however, were lacking to enable clarification of this observation. On the other hand, there were a few cases with drug-resistance mutations that showed good virological suppression. Considering also the detection of drug-resistance mutation in a case as early as 4 months of VL, viral load; ART, antiretroviral therapy; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; and 3TC, lamivudine. Amino acid mutations responsible for drug resistance are colour coded and shown in bold. Amino acid abbreviations: A, alanine; C, cysteine; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; Q, glutamine; R, arginine; V, valine; Y, tyrosine. *HIV-1 drug-resistance mutations were detected according to the latest definition of the International Antiviral Society of USA panel [15] . †URF: unique recombinant form with CRF02_AG/A3 mosaic. ‡Patient was on two-drug regimen at the time of sampling. ART, it is uncertain as to whether drug-resistance mutations existed prior to ART initiation, a situation that has been observed in other ART programmes [37] [38] [39] [40] , or mutations developed during treatment. In general, the drug-resistance prevalence increased with duration of ART, as nine resistance mutations were recorded by 2 years of ART and a total of 25 mutations by 4 years of ART. This feature appears to be common with ART regimen (zidovudine/stavudine lamivudine and nevirapine) commonly used in resource-limited settings [39, 41] .
A number of factors affect access of HIV and AIDS services in the region of the current study; one of which is the low level of education and knowledge about HIV/AIDS, which leads to stigmatization and discrimination [42, 43] . The 2011 Multiple Indicator Cluster Survey, Ghana showed that, out of all regions in Ghana, the Northern Region ranked second highest in terms of stigmatization and discrimination, or even rejection, of a family member found to have HIV. Comprehensive knowledge about HIV and AIDS is crucial in reducing stigma and discrimination. The survey revealed that, despite many years of public sensitization, comprehensive knowledge of methods of preventing HIV transmission is higher in more urban areas, which are usually the more resourced; the highest being in Greater Accra, the capital (47 %) and the Eastern Region (46 %), and lowest in the Northern Region (17 %). Thus, intense discrimination, poverty and resulting damaging emotional hurt of HIV-infected individuals have serious consequences that affect HIV transmission and treatment in the Northern Region. Infected persons may develop self-stigma that makes them forego treatment; or reluctant to pick up their drugs, especially from hospital in their locality or region in order to avoid being recognized.
In a broader context, the population of our study did not differ much in terms of the pattern of predominant mutations. The most prevalent resistance mutation pattern observed (which is, dual-class resistance comprising a combination of lamivudine-resistance mutation M184I/V with one or more of K103N, Y181C and other mutations conferring resistance to NNRTIs) is similar to that reported commonly in treatment-failure cases in sub-Saharan African countries applying the same first-line treatment [44] . Overall, considering the prevalence of drug-resistance mutations observed, nearly half (42 %, 10/24) of the treatment cases studied harboured clinically significant resistance mutations; with nearly half (40 %, 4/10) of this number being virological failure cases. There is a pressing need for virological monitoring in the resource-limited setting of this study to ensure timely switch to second-line ART and avoid accumulation of drug-resistant viruses, which may worsen the already limited treatment options available.
The results of this study were discussed against a background of some limitations: data were not collected on adherence, which is an important predictor of resistance to ART [45] ; and that limited full appreciation of the relevance of drug-resistance mutations observed in relation to the clinical outcome of cases. Challenges of sample storage and transportation over a long distance to the study laboratory also affected sample recovery for analysis. As such, genotypic data could not be acquired for a proportion of the samples, mostly those with low VL, which consequently decreased the number of samples suitable for analyses. Furthermore, genotypic data were obtained through direct nucleotide sequencing, which might lack appreciable sensitivity in detecting minority drug-resistant variants obscured by the wild-type strains. Ultra-deep sequencing, which has greater capacity than direct sequencing in detecting not only minority (1 %) populations, but also the presence of dual or multiple infections of HIV-1 [46] , would be very useful in analysing HIV in a region where several subtypes of the virus are in circulation. Nevertheless, considering the well-structured nature of ART centres nationwide, and the fact that the findings of this study are in consonance with those reported from previous studies at other sites in Ghana and elsewhere, the above-stated limitations could not have significantly impacted the results leading to the study conclusions.
Conclusion
This study documents the occurrence of clinically significant mutations in ART-receiving patients in Tamale in the Northern Region of Ghana. Evidence was found to suggest a failing ART regimen. To the best of our knowledge, there has been hardly any documented study on HIV-1 species characterization and genotypic assessment of ART outcomes in northern Ghana. Accumulation of resistance mutations seriously threatens future treatment options [47] . Therefore, the need to strengthen the laboratory infrastructure and personnel, and ensure that laboratories have the capacity for sustainable laboratory monitoring of pVL, CD4 + T-cell counts and HIV drug-resistance testing necessary to support successful ART scale-up, cannot be overemphasized. Introduction and use of new sequencing technologies such as next-generation sequencing is needed to better clarify HIV-1 species profile as well as prevalence and transmission of drug-resistant HIV-1 variants in Ghana. Finally, owing to the occurrence of virological failure that accompanies roll-out of ART, there is a need for expansion of access to newer antiretroviral drugs from various drug classes to help control HIV/AIDS; not only in Ghana, but in the entire sub-Saharan Africa, which is the most affected region of the world.
